Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The DNA topoisomerase II–DNA cleavable complex (TOP2cc) is a transient, covalent intermediate formed during the catalytic cycle of topoisomerase II enzymes (Nitiss, J. L., 2009, Nature Reviews Cancer). Under normal physiological conditions, topoisomerase II (TOP2) manages DNA supercoiling, tangling, and knotting by creating a temporary double-strand break, passing another DNA duplex through the gate, and then religating the broken strands (Pommier, Y., 2013, Nature Reviews Cancer). This process is vital for essential cellular activities such as DNA replication, transcription, and chromosome segregation during mitosis (UniProt P11388). However, certain chemotherapeutic agents, known as topoisomerase II poisons, specifically target this intermediate by binding to the enzyme-DNA interface and preventing the religation step (StatPearls, 2023). This stabilization of the TOP2cc transforms a necessary cellular tool into a lethal genomic lesion, leading to the accumulation of permanent double-strand breaks. If these breaks are not repaired, they trigger programmed cell death (apoptosis), making the TOP2cc a critical focal point for cancer therapy. While effective against rapidly dividing malignant cells, the persistence of these complexes can also lead to significant side effects, including cardiotoxicity and secondary leukemias, often due to off-target effects on the TOP2B isoform in non-cancerous tissues (Zhang, S. et al., 2012, Nature Medicine).
Stabilization of the covalent enzyme-DNA intermediate (cleavable complex), preventing DNA religation and converting transient breaks into permanent double-strand breaks that trigger apoptosis (Pommier, Y., 2013, Nature Reviews Cancer).
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNA topoisomerase II–DNA cleavable complex (TOP2-DNA CC) (TOP2-DNA CC).